Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of oral namisite in systemic sclerosis
CTR20262811Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nerandomilast in systemic sclerosis (SSc), sponsored by Boehringer Ingelheim. Started Sep 2026; status: active.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20262811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262811.